Precision BioSciences Inc. Common Stock (DTIL)
Stock · NASDAQ · Health Care
$5.78as of 10/16/2026
Price chart
Active signals
DTIL Signal Track Record
How signals performed across all stocks →What DTIL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -6.4% | 40% | September 17, 2026 |
| Bollinger Band Breakout | 23 | -11.0% | 13% | August 18, 2026 |
| Bollinger Band BreakdownActive now | 22 | +1.9% | 55% | June 2, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -6.0% | 33% | September 25, 2026 |
| Any 20-session window (baseline) | -4.1% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DN…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 67
- Website
- precisionbiosciences.com/
Fundamentals
- 1-day range
- $5.98$6.2
- Market cap
- $191.45M
- P/E (trailing)
- —
- P/E (forward)
- -3.32
- EPS (trailing)
- $-2.80
- Dividend yield
- —
- Beta
- 1.44
- Avg. volume
- 269.7K
How Precision BioSciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Precision BioSciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Brown Melinda · September 25, 2026 · Buy1.1K @ $6.27
- Germano Geno J · September 25, 2026 · Buy2.6K @ $6.28
- Brown Melinda · June 3, 2026 · Grant21.0K
- Frankel Stanley · June 3, 2026 · Grant21.0K
- Germano Geno J · June 3, 2026 · Grant21.0K
- Pire Shari Lisa · June 3, 2026 · Grant21.0K
- Buehler Kevin · June 3, 2026 · Grant21.0K
- SMITH J. JEFFERSON · June 1, 2026 · Grant57.4K
- Scimeca Dario · June 1, 2026 · Grant107.6K
- Kelly John Alexander · June 1, 2026 · Grant193.7K
- Michael Amoroso · June 1, 2026 · Grant573.9K
- Buehler Kevin · May 20, 2026 · Option Exercise21.0K
- Frankel Stanley · May 20, 2026 · Option Exercise21.0K
- Brown Melinda · May 20, 2026 · Option Exercise21.0K
- Pire Shari Lisa · May 20, 2026 · Option Exercise21.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.00M
- Total value held
- $87.07M
- Institutional holders
- 75
- Unknown2.24M
- Unknown2.23M
- Unknown1.97M
- Unknown1.66M
- Unknown1.07M
- Unknown995.4K
- Unknown985.1K
- Unknown910.7K
- Unknown597.9K
- Unknown415.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.